182 related articles for article (PubMed ID: 31603660)
1. Prion-like p53 Amyloids in Cancer.
Navalkar A; Ghosh S; Pandey S; Paul A; Datta D; Maji SK
Biochemistry; 2020 Jan; 59(2):146-155. PubMed ID: 31603660
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer.
Silva JL; Cino EA; Soares IN; Ferreira VF; A P de Oliveira G
Acc Chem Res; 2018 Jan; 51(1):181-190. PubMed ID: 29260852
[TBL] [Abstract][Full Text] [Related]
3. Methods to Screen Compounds Against Mutant p53 Misfolding and Aggregation for Cancer Therapeutics.
Ferretti GDDS; da Costa DCF; L Silva J; Pereira Rangel L
Methods Mol Biol; 2019; 1873():265-277. PubMed ID: 30341616
[TBL] [Abstract][Full Text] [Related]
4. Amyloidogenicity of p53: a hidden link between protein misfolding and cancer.
Gong H; Yang X; Zhao Y; Petersen RB; Liu X; Liu Y; Huang K
Curr Protein Pept Sci; 2015; 16(2):135-46. PubMed ID: 25692950
[TBL] [Abstract][Full Text] [Related]
5. Prion-like aggregation of mutant p53 in cancer.
Silva JL; De Moura Gallo CV; Costa DC; Rangel LP
Trends Biochem Sci; 2014 Jun; 39(6):260-7. PubMed ID: 24775734
[TBL] [Abstract][Full Text] [Related]
6. Loss of the p53 transactivation domain results in high amyloid aggregation of the Δ40p53 isoform in endometrial carcinoma cells.
Melo Dos Santos N; de Oliveira GAP; Ramos Rocha M; Pedrote MM; Diniz da Silva Ferretti G; Pereira Rangel L; Morgado-Diaz JA; Silva JL; Rodrigues Pereira Gimba E
J Biol Chem; 2019 Jun; 294(24):9430-9439. PubMed ID: 31028175
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer.
Ano Bom AP; Rangel LP; Costa DC; de Oliveira GA; Sanches D; Braga CA; Gava LM; Ramos CH; Cepeda AO; Stumbo AC; De Moura Gallo CV; Cordeiro Y; Silva JL
J Biol Chem; 2012 Aug; 287(33):28152-62. PubMed ID: 22715097
[TBL] [Abstract][Full Text] [Related]
8. Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor.
Silva JL; Rangel LP; Costa DC; Cordeiro Y; De Moura Gallo CV
Biosci Rep; 2013 Jul; 33(4):. PubMed ID: 24003888
[TBL] [Abstract][Full Text] [Related]
9. The Status of p53 Oligomeric and Aggregation States in Cancer.
de Oliveira GAP; Petronilho EC; Pedrote MM; Marques MA; Vieira TCRG; Cino EA; Silva JL
Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32260447
[TBL] [Abstract][Full Text] [Related]
10. p53 amyloid formation leading to its loss of function: implications in cancer pathogenesis.
Ghosh S; Salot S; Sengupta S; Navalkar A; Ghosh D; Jacob R; Das S; Kumar R; Jha NN; Sahay S; Mehra S; Mohite GM; Ghosh SK; Kombrabail M; Krishnamoorthy G; Chaudhari P; Maji SK
Cell Death Differ; 2017 Oct; 24(10):1784-1798. PubMed ID: 28644435
[TBL] [Abstract][Full Text] [Related]
11. Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity.
Lasagna-Reeves CA; Clos AL; Castillo-Carranza D; Sengupta U; Guerrero-Muñoz M; Kelly B; Wagner R; Kayed R
Biochem Biophys Res Commun; 2013 Jan; 430(3):963-8. PubMed ID: 23261448
[TBL] [Abstract][Full Text] [Related]
12. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
Stiewe T; Haran TE
Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
[TBL] [Abstract][Full Text] [Related]
13. Interdiction in the Early Folding of the p53 DNA-Binding Domain Leads to Its Amyloid-Like Misfolding.
Bergasa-Caceres F; Rabitz HA
Molecules; 2022 Jul; 27(15):. PubMed ID: 35956758
[TBL] [Abstract][Full Text] [Related]
14. Modulation of p53 and prion protein aggregation by RNA.
Cordeiro Y; Vieira T; Kovachev PS; Sanyal S; Silva JL
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):933-940. PubMed ID: 30826454
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of p53 protein aggregation as a cancer treatment strategy.
Kwan K; Castro-Sandoval O; Gaiddon C; Storr T
Curr Opin Chem Biol; 2023 Feb; 72():102230. PubMed ID: 36436275
[TBL] [Abstract][Full Text] [Related]
16. Direct evidence of cellular transformation by prion-like p53 amyloid infection.
Navalkar A; Pandey S; Singh N; Patel K; Datta D; Mohanty B; Jadhav S; Chaudhari P; Maji SK
J Cell Sci; 2021 Jun; 134(11):. PubMed ID: 34085695
[TBL] [Abstract][Full Text] [Related]
17. Blocking mutation independent p53 aggregation by emodin modulates autophagic cell death pathway in lung cancer.
Haque E; Kamil M; Irfan S; Sheikh S; Hasan A; Nazir A; Mir SS
Int J Biochem Cell Biol; 2018 Mar; 96():90-95. PubMed ID: 29355754
[TBL] [Abstract][Full Text] [Related]
18. Targeting mutant p53 for efficient cancer therapy.
Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
[TBL] [Abstract][Full Text] [Related]
19. The aggregation of mutant p53 produces prion-like properties in cancer.
Rangel LP; Costa DC; Vieira TC; Silva JL
Prion; 2014; 8(1):75-84. PubMed ID: 24509441
[TBL] [Abstract][Full Text] [Related]
20. Current strategies to target p53 in cancer.
Chen F; Wang W; El-Deiry WS
Biochem Pharmacol; 2010 Sep; 80(5):724-30. PubMed ID: 20450892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]